Related Experiment Videos
Helicobacter pylori and nonmalignant diseases
Vassili Isakov1, Peter Malfertheiner
1Department of Gastroenterology, Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia. Vassili.Isakov@rambler.ru
Helicobacter
|November 18, 2003
Summary
Eradicating Helicobacter pylori (H. pylori) cures peptic ulcer disease, but many still need medication for symptom relief. The
Area of Science:
- Gastroenterology
- Microbiology
- Internal Medicine
Background:
- Helicobacter pylori (H. pylori) eradication significantly reduces peptic ulcer disease (PUD) globally.
- NSAID use is increasingly a primary cause of PUD complications like bleeding and perforation.
- Some patients with nonulcer dyspepsia benefit from H. pylori eradication.
Purpose of the Study:
- To review the impact of H. pylori eradication on PUD and dyspepsia.
- To evaluate the efficacy of H. pylori eradication strategies in various patient groups.
- To assess the 'test and treat' approach for uninvestigated dyspepsia.
Main Methods:
- Review of recent randomized controlled trials (RCTs) on H. pylori eradication.
- Analysis of systematic reviews on H. pylori prevalence and GERD incidence.
- Evaluation of meta-analyses supporting the 'test and treat' strategy.
Main Results:
- H. pylori eradication cures PUD, yet many patients require antisecretory agents post-eradication.
- Contradictory results exist regarding H. pylori eradication in NSAID users.
- The 'test and treat' strategy for uninvestigated dyspepsia improves symptom resolution more than empirical PPI treatment and reduces endoscopies.
Conclusions:
- H. pylori eradication is crucial for PUD, but symptom management requires further study.
- Long-term cost/efficacy data are needed for H. pylori eradication in nonulcer dyspepsia.
- The 'test and treat' strategy is effective for uninvestigated dyspepsia, reducing healthcare burden.